1. Home
  2. NRXS vs HRTX Comparison

NRXS vs HRTX Comparison

Compare NRXS & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

HOLD

Current Price

$6.80

Market Cap

78.9M

Sector

N/A

ML Signal

HOLD

Logo Heron Therapeutics Inc.

HRTX

Heron Therapeutics Inc.

HOLD

Current Price

$0.46

Market Cap

90.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRXS
HRTX
Founded
2011
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.9M
90.1M
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
NRXS
HRTX
Price
$6.80
$0.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.00
$4.50
AVG Volume (30 Days)
65.7K
2.9M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
22.13
N/A
EPS
N/A
N/A
Revenue
$3,569,282.00
$154,904,000.00
Revenue This Year
$172.91
$15.28
Revenue Next Year
$115.71
$20.29
P/E Ratio
N/A
N/A
Revenue Growth
32.89
7.36
52 Week Low
$2.20
$0.38
52 Week High
$9.33
$1.93

Technical Indicators

Market Signals
Indicator
NRXS
HRTX
Relative Strength Index (RSI) 45.31 43.90
Support Level $6.60 $0.39
Resistance Level $7.63 $0.46
Average True Range (ATR) 0.33 0.03
MACD -0.01 0.01
Stochastic Oscillator 26.01 52.81

Price Performance

Historical Comparison
NRXS
HRTX

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

About HRTX Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Share on Social Networks: